Timbetasin - RegeneRx Biopharmaceuticals
Alternative Names: Fx peptide; GBT-101; GBT-201; RGN-137; RGN-259; RGN-352; RGN-457; TB4; TB4 16-38; Thymosin B4; Thymosin beta 4-16-38; Thymosin beta-4; Thymosin-beta-4-RegeneRx-Biopharmaceuticals; Timbetasin-National-Institutes-of-Health-(USA)/RegeneRx-Biopharmaceuticals; Tß4 - RegeneRx Biopharmaceuticals; Tβ4Latest Information Update: 28 Dec 2023
At a glance
- Originator National Institutes of Health (USA)
- Developer Chonbuk National University; Defiante Farmaceutica; Lenus Therapeutics; RegeneRx Biopharmaceuticals; sigma-tau SpA; United States Army Medical Research Institute of Chemical Defense; Wayne State University; Zhejiang University
- Class Anti-infectives; Anti-inflammatories; Anti-ischaemics; Antibronchitics; Antidementias; Antifibrotics; Eye disorder therapies; Foot disorder therapies; Heart failure therapies; Neuroprotectants; Peptide hormones; Proteins; Skin disorder therapies; Thymus hormones; Vascular disorder therapies
- Mechanism of Action Actin modulators; Amyloid inhibitors; Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Collagen stimulants; Heat-shock protein modulators; MicroRNA modulators; Nerve growth factor stimulants; NF-kappa B inhibitors; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Dry eyes; Keratitis
- Phase II Epidermolysis bullosa
- Preclinical Alzheimer's disease; Corneal disorders
- No development reported Acute kidney injury; Brain injuries; Burns; Chronic granulomatous disease; COVID 2019 infections; Diabetic neuropathies; Eye disorders; Multiple sclerosis; Musculoskeletal disorders; Myocardial infarction; Pressure ulcer; Pulmonary arterial hypertension; Septic shock; Stroke; Varicose ulcer
- Discontinued Alopecia; Bronchiectasis; Cystic fibrosis; Diabetic foot ulcer; Diabetic retinopathy
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Acute kidney injury in USA
- 28 Dec 2023 No recent reports of development identified for preclinical development in Chronic-granulomatous-disease in USA (Intraperitoneal, Injection)
- 28 Nov 2023 No recent reports of development identified for phase-I development in COVID-2019-infections in Unknown (Injection)